Evidence map›Paper›PMID 37152060›Full record

ArticleFrontiers in oncology2023

Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients.

Ping Chen, Haolin Song, Wei Xu, Jin Guo, Jianfei Wang, Juhong Zhou, Xiang Kang, Chaolei Jin, Yubo Cai, Zixuan Feng and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Early screening for liver cancer must be performed.World journal of hepatology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Ping ChenDepartment of Infectious Diseases, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
Haolin SongCollege of Medicine, Zhejiang University, Hangzhou, China.
Wei XuCollege of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Jin GuoShulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Jianfei WangResearch and Development Division, Oriomics Biotech Inc, Hangzhou, China.
Juhong ZhouResearch and Development Division, Oriomics Biotech Inc, Hangzhou, China.
Xiang KangResearch and Development Division, Oriomics Biotech Inc, Hangzhou, China.
Chaolei JinInfection and Immunity Institute and Translational Medical Center of Huaihe Hospital, Henan University, Kaifeng, China.
Yubo CaiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Zixuan FengShulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Hainv GaoDepartment of Infectious Diseases, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
Fengmin LuDepartment of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Lanjuan LiState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.1037742.].

Indexed as

alpha-fetoproteinDCPGAADPBGALADhepatocellular carcinoma

Identifiers

PMID37152060
PMCPMC10154681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.